CSP-2503
# CSP-2503

CSP-2503 is a potent and selective $5-HT_{1A}$ receptor agonist, $5-HT_{2A}$ receptor antagonist, and $5-HT_3$ receptor antagonist of the naphthylpiperazine class. First synthesized in 2003, it was designed based on computational models and QSAR studies. In rat studies, CSP-2503 has demonstrated anxiolytic effects, and thus has been suggested as a treatment for anxiety in humans with a multimodal mechanism of action.

